Keenova

News

Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.

News

Two new pharma companies - Keenova and Par Health - have now emerged from the merger of Mallinckrodt and Endo earlier this year.

News

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.